Loading
A phase 2 trial of Cemiplimab, Fianlimab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma is a phase 2 interventional study registered as NCT06190951 by Regeneron Pharmaceuticals, with 151 participants enrolled, started 2024-09-18 and due to reach its primary completion in 2026-11-02. Interventions recorded: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/